Search Results 901-910 of 13559 for Assay

1. A Study of TNB-383B in Subjects With Relapsed or Refractory Multiple Myeloma - Mayo Clinic

   Serum free light chain (FLC) assay: Involved FLC level ≥ 10 mg/dl (≥ 100 mg/L) and an abnormal serum FLC ratio (< 0.26 or > 1.65). Subject has confirmed ...

2. Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma - Mayo Clinic

   ... assay: involved SFLCs >/= 10 mg/dL (>/= 100 mg/L) and an abnormal SFLC ratio (<0.26 or >1.65). Female participants of childbearing potential must have a ...

3. Controlled Trial Evaluating Avacopan in C3 Glomerulopathy - Mayo Clinic

   ... assay. Currently on dialysis or likely will require dialysis within 7 days after screening. History or presence of any form of cancer within the 5 years ...

4. Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma - Mayo Clinic

   ... assays performed in clinical laboratory improvement amendments (CLIA)-approved laboratories ... assay. Exclusion Criteria: Definitive clinical or radiologic ...

5. Hormone Therapy For Breast Cancer Clinical Trials - Mayo Clinic Research

   The purpose of this study is to recruit 2000 incident cases of primary breast cancer in order to perform laboratory assays to measure frequencies of genetic ...

6. Testing Whether The Addition Of Carboplatin Chemotherapy To Cabazitaxel Chemotherapy Will Improve Outcomes Compared To Cabazitaxel Alone In People With Castrate-Resistant Prostate Cancer That Has Spread Beyond The Prostate To Other Parts Of The Body - Mayo Clinic

   ... assays for TP53, RB1 and PTEN. In addition, while not mandated, CLIA certified next generation sequencing (NGS) of tumor deoxyribonucleic acid (DNA) and/or ...

7. Study of EXE-346 Live Biotherapeutic to Reduce High Bowel Movement Frequency in Subjects With an IPAA (PROF) - Mayo Clinic

   ... assays are generally similar. ... Therefore, assay standardisation is required for more accurate and traceable test results for faecal calprotectin.

8. Fabrice Lucien-Matteoni, Ph.D. - Mayo Clinic Faculty Profiles

   Lucien-Matteoni's lab uses advanced proteomic methodologies, functional assays and animal models to characterize the identity and function of the cancer ...

9. Eva M. Carmona Porquera, M.D., Ph.D. - Mayo Clinic Faculty Profiles

   Likewise, the B cell assays under development will predict patients at risk of developing lung fibrosis and also identify patients that will benefit from B cell ...

10. Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA - Mayo Clinic

    ... assay. Exclusion Criteria: Prior invasive malignancy (except node negative, non-melanomatous skin cancer) unless disease free for a minimum of 1095 days (3 ...